E.g., 03/21/2019
E.g., 03/21/2019
Titlesort descending Category Credit Event date Price
Life Long Learning Knowledge Assessment Course: Urothelial Bladder Cancer Webcast (2018)
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
$99.00 This activity was taken from the 2017 Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam.
Life Long Learning Prep Course: A Focused Review Webcast - Module 1: Oncology, Urinary Diversion and Adrenal (2018) $1,345.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Life Long Learning Prep Course: A Focused Review Webcast - Module 2: Calculi, Laparoscopy-Robotics and Upper Tract Obstruction (2018) $1,345.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Life Long Learning Prep Course: A Focused Review Webcast - Module 3: Impotence, Infertility and Andrology (2018) $1,345.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Life Long Learning Prep Course: A Focused Review Webcast - Module 4: Neurogenic Bladder, Voiding Dysfunction, Female Urology, BPH & Urethral... $1,345.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
Male Sexual Dysfunction for APPs (2017)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$40.00 Member only benefit! In this era of increasing responsibility for primary care physicians and primary mid-level providers, it is important to recognize male sexual dysfunction may be mitigated due to advance lifestyle changes and risk factors need to be addressed and altered. Many APN/PAs also do not know what tests are appropriate for the work-up of male sexual dysfunction. Basic knowledge and understanding of male sexual dysfunction and its reflection of underlying health issues for the patient is needed.
Management of Common Dilemmas in Prostate Cancer Diagnosis, Staging & Treatment Webcast 058IC (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 We will discuss common PSA dilemmas: 1. Who should be screened? 2. What is the role of MRI in biopsy naive and men with prior negative biopsy? 3. What other markers can be used to determine whether biopsy or rebiopsy is warranted? 4. Whats the optimal biopsy strategy: Transrectal, transperineal, MRI-cognitive, MRI fusion? 5. Discuss Active Surveillance, Rad Px, XRT and focal therapy pros and cons for PSA-detected cancer. 6. What is role of adjuvant v. salvage XRT post-RP? 7. Review new PET scans for biochemically recurrent disease after RP or XRT. 8.
Management of Prostate Cancer: A Case-Based Approach with Emphasis on Integrating New Molecular Diagnostics into Clinical Practice Webcast 078IC (...
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 This course will provide a practical, evidence-based approach for the management of everyday problems in the management of prostate cancer, using a case-based approach with examples from real practice.
Masterclass Webinar: Testosterone Deficiency (Espanol) (2018) $0.00 AUA is pleased to bring this FREE 60-minute, non-cme online educational series, presented in Spanish to the global urologic community.  Dr. Alejandro Rodriguez is joined by expert faculties Drs. Rafael Carrion, Adrian Momesso and Miguel Rivero for an exciting program featuring didactic lectures from AUA2018 Second Opinion Cases on Testosterone Defiency. Specific topics include:
Multi-parametric Ultrasound in the Diagnosis of Prostate Cancer Webcast (2017)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Member only benefit! Transrectal ultrasound is critical to biopsy guidance for the diagnosis of prostate cancer. However, ultrasound has the ability to improve diagnostic accuracy and may perform as well as multi-parametric MRI in identifying suspicious lesions. This course will familiarize participants with gray-scale ultrasound, color and power Doppler ultrasound, elastography and contrast-enhanced ultrasound as modalities which alone or in combination may improve the diagnosis of prostate cancer. 
New Muscle Invasive Bladder Cancer Guideline Webcast (2017)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Novel Agents & Concepts in the Management of Hormone-Naive & Castrate-Resistant Prostate Cancer Webcast 043IC (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed.ACKNOWLEDGEMENTSThis educational series is supported by independent educational grants from:
Oral Board Study Guide App (iOS and Android) $299.00 The AUA Oral Board Study Guide App features 68 interactive protocols in 34 topic areas. Developed by leading experts in urology, the app has been specifically designed for urologists preparing to take this examination and includes a strong emphasis on AUA Guidelines with direct access to the AUA Guidelines and the AUA Urology Core Curriculum for AUA members. Available for use on Apple and Android devices!
Patient Safety Course (2018)
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
$0.00 The Patient Safety Course is designed to provide urologists and the urology care team with the knowledge required to apply appropriate patient safety procedures in a urologic practice.  Urology specific examples will help learners understand patient safety concepts, how safety issues arise, and how they can be mitigated.
Practical Management of Metastatic Prostate Cancer: Guidelines and Beyond Webcast (2017)
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Non-Physician Participation
$0.00 Urologists continue to indicate one of the greatest educational needs in treating CRPC patients is the sequencing of agents. With the numerous new treatments now available to urologists to manage the CRPC patient, sequencing and managing the side effects of each treatment have become increasingly important. In addition, studies are demonstrating that earlier treatment with these systemic agents has improved efficacy.

Pages